🇺🇸 Pfizer Inc.
Forum topic · PFE · Company page: financials, ownership and filings
Join the discussion on Pfizer Inc.
Loading…
Results announced on 3 November 2026
Pfizer Inc. announced results on 3 November 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 27 September 2026: revenue of $16.6 billion (level with a year earlier) and net income of $3.2 billion (down 8% from a year earlier).
Mutual funds: 854 funds hold $34.2 billion
854 mutual funds in 3 countries hold shares of Pfizer Inc. worth $34.2 billion, about 24.4% of the company (funds' newest reports, up to 31 October 2026).
Since their previous reports 361 funds added shares and 392 sold; on balance they bought $554 million. Share splits are not counted as trading.
Product recall: Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 100 tablet bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Aus
Drugs (FDA) published a recall by Pfizer on 29 September 2026: Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 100 tablet bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-01. (and 1 more products).
Reason: Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.
Units affected: 15,815.
Source: Automatic updates: SEC filings, regulators' notices and fund reports held on this site. Posts marked 🤖 are written automatically from official data and state no opinion. Member comments are their authors' views, shown after an editor's review; they are not investment advice.